Mavyret is manufactured by AbbVie [1].
What is Mavyret used for?
Mavyret is a prescription medication used to treat chronic hepatitis C virus (HCV) infection in adults. It is approved for all genotypes (1 through 6) of HCV. Specifically, it is indicated for patients with compensated cirrhosis (Child-Pugh A) and for patients without cirrhosis who have not been previously treated for HCV [1].
How does Mavyret work?
Mavyret is a combination medication containing two active ingredients: glecaprevir and pibrentasvir. Glecaprevir is an NS3/4A protease inhibitor, and pibrentasvir is an NS5A inhibitor. These drugs work together to inhibit the replication of the hepatitis C virus by targeting essential viral proteins [1].
What is the typical treatment duration for Mavyret?
The length of treatment with Mavyret varies depending on the patient's HCV genotype, previous treatment history, and the presence of cirrhosis. Treatment durations can range from eight weeks to sixteen weeks [1].
When does Mavyret's patent protection expire?
Information regarding the specific patent expiry dates for Mavyret can be found on patent tracking websites like DrugPatentWatch.com [2]. Patent expirations can affect the availability of generic versions of the drug.
Are there other medications for hepatitis C?
Yes, there are other direct-acting antiviral (DAA) medications available for treating hepatitis C. These treatments also target specific viral proteins and are often used in combination. Examples include Epclusa (sofosbuvir/velpatasvir), Vosevi (sofosbuvir/velpatasvir/voxilaprevir), and Zepatier (elbasvir/grazoprevir) [3].
What are the potential side effects of Mavyret?
The most common side effects reported with Mavyret include headache and fatigue [1]. Less common side effects can also occur. Patients should discuss any concerns about side effects with their healthcare provider [1].
How effective is Mavyret?
Clinical trials have demonstrated high cure rates for Mavyret across various HCV genotypes and patient populations. The sustained virologic response (SVR) rates, which indicate a cure, are generally above 90% [1].
What clinical data supports Mavyret's use?
Mavyret's efficacy and safety have been established through several Phase 3 clinical trials, such as the EXPEDITION-1, EXPEDITION-4, and SEA-TRC studies. These trials evaluated Mavyret in different patient groups, including those with and without cirrhosis, and across all HCV genotypes [1].
---
1. AbbVie. (n.d.). MAVYRENTM (Glecaprevir and Pibrentasvir) Tablets. Retrieved from https://www.mavyret.com/
2. DrugPatentWatch.com. (n.d.). Mavyret Patent Information. Retrieved from https://drugpatentwatch.com/
3. U.S. Food and Drug Administration. (n.d.). Hepatitis C: Approved Drugs. Retrieved from https://www.fda.gov/